BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells $70,600.00 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Sarah Aebersold sold 4,000 shares of the business's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $17.65, for a total transaction of $70,600.00. Following the completion of the transaction, the insider now owns 65,843 shares in the company, valued at $1,162,128.95. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Sarah Aebersold also recently made the following trade(s):

• On Wednesday, February 21st, Sarah Aebersold sold 58 shares of BioLife Solutions stock. The shares were sold at an average price of $17.35, for a total transaction of $1,006.30.
• On Tuesday, January 23rd, Sarah Aebersold sold 336 shares of BioLife Solutions stock. The shares were sold at an average price of $17.11, for a total transaction of $5,748.96.

BioLife Solutions Trading Down 1.6 %

Shares of BioLife Solutions stock traded down $0.28 on Wednesday, reaching $17.32. The company had a trading volume of 346,307 shares, compared to its average volume of 421,253. The firm's 50 day moving average price is $17.73 and its two-hundred day moving average price is $15.07. The firm has a market cap of $784.60 million, a PE ratio of -11.39 and a beta of 1.67. BioLife Solutions, Inc. has a 52-week low of $8.92 and a 52-week high of $24.50. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.83 and a current ratio of 2.86.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its quarterly earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.02. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. Sell-side analysts predict that BioLife Solutions, Inc. will post -0.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioLife Solutions

Large investors have recently modified their holdings of the company. Nisa Investment Advisors LLC increased its position in shares of BioLife Solutions by 167.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 1,020 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of BioLife Solutions in the 1st quarter valued at approximately $36,000. Cubist Systematic Strategies LLC purchased a new stake in shares of BioLife Solutions in the 1st quarter valued at approximately $36,000. GAMMA Investing LLC purchased a new stake in shares of BioLife Solutions in the 4th quarter valued at approximately $41,000. Finally, US Bancorp DE increased its position in shares of BioLife Solutions by 374.6% in the 4th quarter. US Bancorp DE now owns 2,520 shares of the medical equipment provider's stock valued at $41,000 after purchasing an additional 1,989 shares during the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.